Table 3 Main results of the three RCT investigating the efficacy of AIs in preventing symptoms recurrence after surgery for endometriosis (secondary outcome)
From: Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review
Authors | Treatment | Length of treatment | Length of follow-up after discontinuation of hormonal therapy | Results |
|---|---|---|---|---|
Soysal et al. [39] | - anastrozole (1 mg/day) or placebo - goserelin 3.6 mg/4 weeks - elemental calcium (1200 mg/day), vitamin D (800 I.U./day) | 6 months | 24 months | The recurrence rate was 7.5% (3/40) in patients receiving anastrozole and goserelin and 35.0% (14/40) in patients receiving goserelin alone. The median time to detect symptom recurrence was > 24 months in patients receiving anastrozole and goserelin and 17 months in patients receiving goserelin alone. |
Roghaei et al. [45] | - letrozole 2.5 mg/day or danazol (600 mg/day) or placebo - elemental calcium (1000 mg/day), vitamin D (880 I.U./day) | 6 months | 0 months | At the end of the treatment, the intensity of pain symptoms was significantly lower in patients treated with letrozole or danazol than in those treated with placebo. |
Alborzi et al. [46] | letrozole (2.5 mg/day) or triptorelin (3.75 mg/4 weeks) or no treatment | 2 months | 12 months | The rate or recurrence was 6.4% (3/47) in patients treated with letrozole, 5.0% (2/40) in patients treated with triptorelin and 5.3% (3/57) in patients receiving no treatment (not significant). |